GCG and metabolic disease: The fusion of GLP-1 with FGF21 was motivated by their complementary pharmacology, thereby addressing the three criteria for an ideal combination therapy to treat metabolic disease: improved glucose metabolism, decreased food intake, and enhanced energy expenditure.